en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2020
vol. 95
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Artykuł oryginalny

The role of serum cytokeratin 18 and platelet count as non-invasive markers in the diagnosis of nonalcoholic fatty liver disease in children with type 1 diabetes mellitus

Nagwa A. Ismail
1
,
Abeer M. N. E. Abd ElBaky
1
,
Mona H. Ibrahim
2
,
Wafaa Mohamed Ezzat
3
,
Yasser A. Elhosary
3
,
Eman A. Mostafa
1
,
Hoda H. Ahmed
1
,
Inas Abdel Rasheed
2

1.
Department of Paediatrics, Medical Research Division, National Research Centre, Cairo, Egypt
2.
Department of Clinical Pathology, Medical Research Division, National Research Centre, Cairo, Egypt
3.
Department of Internal Medicine, National Research Centre, Cairo, Egypt
Pediatr Pol 2020; 95 (3): 141–148
DOI: https://doi.org/10.5114/polp.2020.100990
Data publikacji online: 2020/10/30
Plik artykułu:
- The role of serum cytokeratin.pdf  [0.21 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Carey IM, Critchley JA, DeWilde S, et al. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care 2018; 41: 513e21.
2. Farhan R, Alzubaidi MA, Ghayyib SM. Fatty Liver Disease in Children and Adolescents with Type 1 Diabetes Mellitus (Clinical andDiagnostic aspects). J Clin Gastroenterol Hepatol 2018; 2: 14.
3. Im SS, Kang SY, Kim SY, et al. Glucose stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes. Diabetes 2005; 54: 1684-1691.
4. Krishnan S, Short KR. Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes. J Cardiometab Syndr 2009; 4: 50e6.
5. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393.
6. Pei RJ, Danbara N, Tsujita-Kyutoku M, et al. Immunohistochemical profiles of Mallory body by a panel of anticytokeratin antibodies. Med Electron Microsc 2004; 37: 114-118.
7. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
8. Calvert VS, Collantes R, Elariny H, et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reversephase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007; 46: 1315-1316.
9. Elalfy H, Besheer T, Elhammady D, et al. Model for Non-Invasive Diagnosis of NAFLD Incorporating Caspase 3-Cleaved Cytokeratin-18: A Clinical, Serological, and Immunohistochemical Analysis. Hepat Mon 2018; 18: e60168.
10. Ozhan H, Aydin M, Yazici M, et al. Mean platelet volume in patients with non-alcoholic fatty liver disease. Platelets 2010; 21: 29-32.
11. Das SK, Mukherjee S, Vasudevan DM, Balakrishnan V. Comparison of haematological parameters in patients with non-alcoholicfatty liver disease and alcoholic liver disease. Singapore Med J 2011; 52: 175-181.
12. Imajo K, Yoneda M, Nakajima A. Are platelets counts useful for detecting the grade of steatosis? Hepat Mon 2015; 15: e28957.
13. Yoneda M, Fujii H, Sumida Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liverdisease. J Gastroenterol 2011; 46: 1300-1306.
14. Suzuki K, Kirikoshi H, Yoneda M, et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stagenon-alcoholic steatohepatitis. Hepatol Res 2010; 40: 693-700.
15. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
16. Garjani A, Safaeiyan A, Khoshbaten M. Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepat Mon 2015; 15: e24449.
17. Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 2014; 20: 10851-10863.
18. Egyptian growth curves. Diabetes Endocrine Metabolism Pediatric Unit Cairo University Childern’s Hospital 2009. Available at: http:// dempuegypt.blogspot.com (access: 10 October 2019).
19. Cameron N. The methods of auxological anthropology. In: Human growth 3 methodology. Falkner F, Tanner JM (eds.). Plenum Press, New York 1986: 3-46.
20. Ismail NA, Ragab SA, Abd El-Baky A, et al. Relation between serum progranulin, inflammatory markers and visceral fat in childhood obesity. Adv Biosci Biotechnol 2013; 4: 1030-1038.
21. Palmeri ML, Wang MH, Dahl JJ, et al. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol 2008; 34: 546-558. 22. Alisi A, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009; 155: 469-474.
22. Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
23. Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138: 1357-1364.
24. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
25. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
26. Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019; 5: 11-21.
27. Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53: 713-718.
28. Garjani A, Safaeiyan A, Khoshbaten M. Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepat Mon 2015; 15: e24449.
29. Saremi Z, Rastgoo M, Mohammadifard M, et al. Comparison of platelet number and function between nonalcoholic fatty liver disease and normal individuals. J Res Med Sci 2017; 22: 75.
30. Yoneda M, Fujii H, Sumida Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 1300-1306.
31. Feldstein AE, Wieckowska A, Lopez AR, et al. Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 2009; 50: 1072-1078.
32. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a “growing” problem? J Hepatol 2007; 46: 1133-1142.
33. Vuppalanchi R, Jain AK, Deppe R, et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 2121-2130.
34. Mandelia C, Collyer E, Mansoor S, et al. Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2016; 63: 181-187.
35. Sanyal A, Cusi K, Hartman ML, et al. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. Journal of Investigative Medicine 2017; 66: 661- 668.
36. Boyraz M, Hatipoğlu N, Sari E, et al. Non-alcoholic fatty liver disease in obese children and the relationship between metabolicsyndrome criteria. Obes Res Clin Pract 2014; 8: e356-363.
37. Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009; 15: 4387-4391.
Copyright: © 2020 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.